ALKERMES | ALKS - Gross Profit On Sales

Stock Price
37.48
Daily Change
-0.88 -2.29%
Monthly
11.00%
Yearly
19.29%
Q2 Forecast
36.35

ALKERMES reported $331.33M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
ALKERMES USD 331.33M 7M Mar/2026
Amgen USD 6.89B 415M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ionis Pharmaceuticals USD 243M 48M Mar/2026
J&J USD 17.24B 642M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Otsuka Holdings JPY 456.25B 1.16B Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026